In the ongoing exercise of TO 6 B, CLS has agreed on top down underwriting commitments with qualified investors. The underwriting commitments comprises a total of SEK 7 million, corresponding to approximately 30 per cent of the issue proceeds that the Company can raise through the exercise of TO 6 B.

The underwriting commitments constitute a so-called "top-down" or "top guarantee", which means that if TO 6 B is exercised to approximately 70 per cent, underwriting subscription is executed for the remaining 30 per cent up to a fully subscribed TO 6 B. The underwriting commitments is thus added to the existing subscription level for TO 6 B and is intended to ensure the last part of the subscription in the warrant exercise in the event that all TO 6 B are not exercised by existing holders. For the underwriting commitments, a cash compensation of fifteen (15) per cent of the underwritten amount is paid. Of the total underwritten amount, approximately SEK 1.2 million has been secured via an advance transaction, the remaining amount has not been secured via an advance transaction, bank guarantee or similar.

In the event that the underwriting commitments are activated, subscription of shares will take place through a directed share issue carried out after the exercise period for TO 6 B has ended. Subscription in such a directed share issue shall be made at the established price for TO 6 B and only to the extent TO 6 B has not been exercised by existing holders within the scope of the underwriting commitments (corresponding to a maximum of 70,000,000 B-shares in the Company). The Board of Directors will not decide on the directed share issue to use the underwriting commitment in case the Board of Directors does not consider it justifiable taking into account a customary issue cost.

Information brochures about the Company and the offer (in Swedish and English) and other material for investors are available on CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se). Complete terms and conditions and instructions for warrants of series TO 6 B are available on the Company's website.

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

Website: www.sedermera.se

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: www.clinicallaser.se

This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-02-2024 07:55 CET.